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BACKGROUND: Attention-deﬁcit/hyperactivity disorder (ADHD) is the most common childhood neurodevelopmen-
tal disorder, and boys are two to three times more likely to develop ADHD. Maternal polycystic ovary syndrome
(PCOS), a common metabolic disorder associated with excess circulating androgens, has been associated with
increased risk for autism spectrum disorder in the offspring. In this study, we aimed to investigate whether maternal
PCOS increases the risk for ADHD in the offspring.
METHODS: We conducted a matched case-control study using health and population data registers for all children
born in Sweden from 1984 to 2008. Maternal PCOS was deﬁned by ICD-coded register diagnosis. The outcome of
ADHD was deﬁned as an ICD-coded register diagnosis of ADHD and/or registered prescription of medications to
treat ADHD. A total of 58,912 ADHD cases (68.8% male) were identiﬁed and matched to 499,998 unaffected controls
by sex and birth month and year.
RESULTS: Maternal PCOS increased the odds of offspring ADHD by 42% after adjustment for confounders (odds
ratio [OR], 1.42; 95% conﬁdence interval [CI], 1.26–1.58). Exclusion of ADHD cases with comorbid autism spectrum
disorder attenuated but did not explain the relationship (OR, 1.34; 95% CI, 1.18–1.52). The risk was somewhat
elevated for ADHD with comorbid autism spectrum disorder (OR, 1.76; 95% CI, 1.37–2.26). The risk for ADHD was
higher among obese mothers with PCOS (OR, 1.68; 95% CI, 1.31–2.17) and was highest among obese mothers with
PCOS and other features of metabolic syndrome (OR, 2.59; 95% CI, 1.02–6.58).
CONCLUSIONS: This study provides evidence that maternal PCOS may subtly inﬂuence the neurodevelopment of
the offspring, resulting in increased risk for neurodevelopmental disorders such as ADHD.
Keywords: Attention-deﬁcit disorder with hyperactivity, Autism spectrum disorder, Comorbidity, Epidemiology,
Matched case-control study, Polycystic ovary syndrome, Prospective studyISShttp://dx.doi.org/10.1016/j.biopsych.2016.09.022Attention-deﬁcit/hyperactivity disorder (ADHD) is the most com-
monly diagnosed psychiatric disorder in childhood, with a prev-
alence of 4% to 12%, though symptoms often persist into
adulthood (1–3). Though there is a substantial genetic component
to ADHD risk, multiple environmental factors and gene–environ-
ment interactions have been identiﬁed (4–6). ADHD is a sexually
dimorphic condition, with boys being two to three times more
likely to receive a diagnosis (7). Sex hormones can modify brain
development (8) and may explain the male-skewed risk for certain
neurodevelopmental disorders. Brain regions involved in ADHD,
such as the hippocampus, prefrontal cortex, striatum, and
amygdala, are inﬂuenced by sex hormone signaling during
development (9,10). ADHD often co-occurs with autism spectrum
disorder (ASD), another male-skewed disorder, and the two
conditions may share causal pathways (11). Although increased
exposure to prenatal androgens has been noted in ASD (12), the
relationship between prenatal hormones and ADHD risk has not
been explored.& 2016 Society o
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SEE COMMENTAPolycystic ovary syndrome (PCOS) is the most common
endocrine disorder in women of childbearing age, affecting
5% to 15% of women and characterized by hyperandrogen-
ism, ovarian dysfunction, and polycystic ovarian morphology
(13). The causes of PCOS are not clear, but there is evidence
for a genetic susceptibility to the disorder (14). Some studies
support an interaction between genetic susceptibility and
the inﬂuence of maternal environment, including in utero
exposure to excess androgens, in the etiology of PCOS
(15,16). Furthermore, weight gain and obesity are of impor-
tance for the development of PCOS. Obesity is closely related
to the hyperinsulinemia that enhances hyperandrogenemia in
women with PCOS (17). Hyperandrogenism in turn contributes
to the adiposity, insulin resistance, and hyperinsulinemia that
are common in PCOS (13,18). PCOS often emerges during
puberty, but it may also develop later in reproductive years, for
instance, as a result of weight gain (13,19). Maternal PCOS
is a potential source of excess androgen exposure for thef Biological Psychiatry. This is an open access article under the
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Psychiatryfetus (20,21). Maternal diagnosis of PCOS is associated with
increased risk for ASD in the offspring, particularly in obese
mothers (22). We hypothesized that maternal PCOS may also
inﬂuence the offspring’s risk for ADHD.
Here, we test this hypothesis by examining the relationship
between maternal diagnosis of PCOS and risk for clinically
diagnosed ADHD in the offspring in a Swedish nationwide
case-control study using prospectively collected health regis-
ter data. We explored whether high levels of comorbidity
between ADHD and ASD could explain this relationship.METHODS AND MATERIALS
Study Population
We used similar methods for the population selection and
statistical methods as in our recent study that examined the
relationship between maternal diagnosis of PCOS and risk for
offspring ASD (22). All data are derived from linkages held by
Statistics Sweden and the National Board of Health and
Welfare, containing routinely collected health and sociodemo-
graphic data on the entire population of Sweden and cross-
linked by each resident’s unique national registration number
(23). The eligible study population consisted of all individuals
born in Sweden from 1984 to 2011 and followed until
December 31, 2011. We matched all cases of ADHD (see
below) in the study population with up to 10 living controls
who were without an ADHD diagnosis at the end of the follow-
up period. Controls were matched by sex and birth month and
year. After exclusion of children not born in Sweden, born after
2008, from a multiple birth, adopted, and those with missing
covariate data (Figure 1), the ﬁnal sample consisted of 58,912
ADHD cases matched to 499,998 controls, with a case to
control ratio between 1:2 and 1:10. This study was approved
by the regional ethical review board at Karolinska Institutet.
Informed consent was not required for the analysis of anony-
mized register data.
ADHD Case Ascertainment
We used a previously validated two-step approach for iden-
tifying cases of ADHD (24). First, ADHD case status as of
December 31, 2011, was deﬁned as a recorded diagnosis of
ICD-10 code F90 or ICD-9 code 314 within the National
Patient Register (NPR). The NPR provides data on inpatient
care since 1973 and outpatient specialist physician care since
2001. The coverage of the NPR is approximately 99% of all
somatic discharge diagnoses, and the validity of the diagno-
ses is generally high (25). As a second step, we searched the
Prescribed Drug Register (PDR) for anyone recorded as
receiving prescriptions for ADHD medications (methylpheni-
date [Anatomical Therapeutic Chemical (ATC) Classiﬁcation
System code N06BA04] or atomoxetin [ATC code N06BA09]).
The PDR contains data on medications dispensed to the entire
population in Sweden since July 1, 2005. Receipt of a
prescription for ADHD medications is a useful proxy for an
ADHD diagnosis because Swedish medical guidelines man-
date that ADHD medications should only be prescribed by a
psychiatric specialist and after other (nonpharmacological)
interventions have failed.2 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalExposure
Maternal PCOS status was classiﬁed according to any lifetime
recorded diagnosis (ICD-8 code 256.90, ICD-9 code 256E,
and ICD-10 code E28.2) within the NPR, supplemented by
diagnoses in the Medical Birth Register (MBR). The MBR
includes information on pregnancy, delivery, and the neonatal
period for approximately 98% of births in Sweden since 1973.
We used lifetime diagnoses of PCOS as the exposure because
PCOS is a longitudinal disorder with hormonal and metabolic
manifestations through the life span (26,27).
Covariates
Covariates were identiﬁed a priori as potential confounding
factors and/or risk factors for ADHD. Maternal and paternal
ages at the time of birth were categorized as ,25, 25 to 29, 30
to 34, 35 to 39, and $40 years. Data on family income after
deduction of taxes were obtained from the Integrated Data-
base for Labor Market Research, adjusted for family size, and
categorized into quintiles according to birth year. The highest
education of either parent at the time of birth was classiﬁed as
years of completed formal education (#9, 10–12, or $13
years). Parental history of psychiatric inpatient and outpatient
treatment before the birth of the index child (yes/no) was
deﬁned as any psychiatric diagnosis (chapter V of ICD-8 and
ICD-9 or chapter F of ICD-10) recorded in the NPR. Maternal
migrant status was categorized as born in Sweden or not.
We explored whether obstetric complications inﬂuenced
the ﬁndings of our main analysis due to reports of increased
obstetric complications in mothers with PCOS (28) and
associations of obstetric complications with ADHD (29). Apgar
score at 5 minutes was categorized as ,7 or $7 and
supplemented by Apgar score at 1 minute when data on
Apgar score at 5 minutes were not available. Size for gesta-
tional age was categorized as small for gestational age or not.
Preterm birth was categorized as ,37 weeks or not. Pree-
clampsia was classiﬁed according to ICD-8 codes 637.03 to
637.04 and 637.09 to 637.10, ICD-9 codes 642E to 642H, and
ICD-10 codes O14 to O15 for diagnoses recorded within the
MBR or in the NPR during the 9 months before and 1 month
after birth of the index child. Birth order was categorized as
ﬁrst born or not according to the MBR.
Obesity and other features of metabolic syndrome are
common in PCOS and are related to more severe hyper-
androgenemia in women with PCOS (30,31). Furthermore,
elevated maternal body mass index (BMI) has been associated
with risk for ADHD (32). Thus, we explored the inﬂuence of
prepregnancy BMI and metabolic syndrome on the relation-
ship between maternal PCOS and offspring ADHD.
To calculate maternal baseline BMI (in kg/m2), we used
weight and height data recorded at the ﬁrst visit to a maternal
health clinic (33). Data were available on 71% of the mother-
child pairs in our analytical sample (Figure 1). Maternal base-
line BMI was categorized by standard convention (34): under-
weight (BMI , 18.5 kg/m2), normal (18.5 # BMI , 25 kg/m2),
overweight (25 # BMI , 30 kg/m2), and obese (BMI $ 30 kg/
m2). Mothers were classiﬁed as having a prior diagnosis of
diabetes mellitus according to the codes ICD-8 250; ICD-9
250, 648A, and 790C; and ICD-10 E10 to E11 and O24.0 to
O24.1 if at least one diagnosis was recorded prior to and
Figure 1. Derivation of the Swedish
Youth Cohort analytical sample.
Cases classiﬁed as to whether identi-
ﬁcation occurred through a registered
ICD diagnosis, through the Prescribed
Drug Register (PDR), or both. ADHD,
attention-deﬁcit/hyperactivity disor-
der; ASD, autism spectrum disorder;
BMI, body mass index.
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Type 1 and type 2 diabetes were grouped together because
these distinctions were not recorded before the use of ICD-10
coding. A similar strategy was used to identify essential
hypertension using the following ICD codes: ICD-8 400 to
404; ICD-9 401 to 404 and 642A to 642C; and ICD-10 I10 to
I13 and O10 to O11.
Women with PCOS more often use fertility treatments (13).
Information on fertility treatment, including in vitro fertilization,
intracytoplasmic injection, ovulation induction, or other treat-
ment, was available in the MBR from 1995 onward.
Medications such as valproate (ATC code N03AG01) and
antipsychotics (ATC code N05A) are reported to induce featuresof PCOS in women (35,36). Use of these medications during
pregnancy has been associated with neurodevelopmental dis-
orders in the offspring (37). Pharmacological interventions for
mothers with PCOS, such as spironolactone (ATC code
C03DA01) and metformin (ATC code A10BA02), might lower
androgen and insulin levels and attenuate risk for ADHD (38,39).
Information on mothers’ medication during pregnancy was
available in the PDR from 2005 onward.Statistical Analysis
Analyses were performed using SPSS, version 20 (IBM Corp.,
Armonk, NY). Conditional logistic regression was used toBiological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 3
Table 1. Selected Characteristics of Birth Cohorts From 1984 to 2008 in the Swedish Population
ADHD Cases, n (%) Controls, n (%) Analysis
Characteristic (N 5 58,912) (N 5 499,998) pa
ASD Diagnosis 9570 (16.2) 3970 (0.8) ,.001
Maternal PCOS 404 (0.7) 1937 (0.4) ,.001
Mother’s Country of Birth ,.001
Sweden 52,411 (89) 425,919 (85.2)
Other 6501 (11) 74,079 (14.8)
Parental History of Psychiatric Care
Mother 24,584 (41.7) 102,914 (20.6) ,.001
Father 18,280 (31) 78,691 (15.7) ,.001
Lowest Quintile for Family Income 10,403 (17.7) 78,936 (15.8) ,.001
Parents With #9 Years of Schooling 16,055 (27.3) 81,831 (16.4) ,.001
Born First 25,404 (43.1) 208,436 (41.7) ,.001
Preeclampsia 2320 (3.9) 15,931 (3.2) ,.001
Apgar Score ,7 at 5 Minutes 753 (1.3) 4667 (0.9) ,.001
Missing data 426 (0.7) 3006 (0.6)
Gestational Age ,.001
Preterm birth (,37 weeks) 4123 (7.0) 24,660 (4.9)
Postterm birth ($42 weeks) 4113 (7.0) 37,413 (7.5)
Missing data 122 (0.2) 641 (0.1)
Size for Gestational Age ,.001
Small for gestational age 2216 (3.8) 11,820(2.4)
Large for gestational age 2211 (3.8) 17,716 (3.5)
Missing data 326 (0.6) 2052 (0.4)
Maternal BMI in Early Pregnancy ,.001
BMI , 18.5 kg/m2 1651 (2.8) 13,378 (2.7)
18.5 # BMI , 25 kg/m2 25,480 (43.3) 244,238 (48.8)
25 # BMI , 30 kg/m2 9440 (16) 72,835 (14.6)
BMI $ 30 kg/m2 4815 (8.2) 24,895 (5)
Missing data 17,526 (29.7) 144,652 (28.9)
Parental Age at Delivery, Years Mean (SD) Mean (SD) pb
Maternal 27.65 (5.43) 28.77 (5.06) ,.001
Paternal 30.71 (6.54) 31.65 (6.04) ,.001
ADHD, attention-deﬁcit/hyperactivity disorder; ASD, autism spectrum disorder; BMI, body mass index; PCOS, polycystic ovary syndrome.
aCase-control differences were tested using a χ2 test.
bCase-control differences were tested using an independent-sample t test.
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PCOS and offspring ADHD, ﬁrst as an unadjusted estimate
(model 1) and then in a model adjusted for maternal and
paternal age, parental psychiatric history, parental income and
education, birth order, and maternal country of birth (model 2).
Mothers without PCOS were used as the referent group. To
explore the inﬂuence of obstetric complications on the
maternal PCOS–offspring ADHD relationship, we used a
model additionally adjusted for the following obstetric factors:
Apgar score, preterm birth, small for gestational age, and
preeclampsia (model 3). Results were examined for the total
analytical sample, in sex-stratiﬁed models, and in the meta-
bolic subcohort (Figure 1). For the metabolic subcohort, we
additionally adjusted for maternal BMI in early pregnancy
(model 4).
Because ASD is often diagnosed with ADHD and maternal
PCOS may increase the risk for ASD (22), we tested whether
associations observed between maternal PCOS and offspring
ADHD were driven by the comorbidity between the disorders4 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalby stratifying ADHD cases on the basis of comorbid ASD and
their controls (Figure 1) and repeating the analysis of maternal
PCOS (models 1–3).
Last, we tested for the effects of worsening cardiometabolic
risk proﬁles among women with PCOS. We explored whether
the risk for offspring ADHD was different among mothers with
the following a priori deﬁned mutually exclusive categories: no
PCOS (referent), PCOS, PCOS with overweight, PCOS with
obesity, and PCOS with obesity and indications of metabolic
syndrome. Mothers without PCOS were used as the referent
group (including women without PCOS but affected by over-
weight, obesity, diabetes, or essential hypertension).Sensitivity Analyses
Because it is possible that cases ascertained by prescription
drug records only may differ from cases with a recorded
diagnosis, we excluded cases ascertained by PDR records
only and repeated models 1 to 3.
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might inﬂuence offspring health. Therefore, we repeated the
analysis for children born after 1995 (27,194 cases, 227,324
controls), with further adjustment of model 2 for use of fertility
treatment.
Because migrants to Sweden may experience differential
access to care and thus may be less likely to receive
diagnoses of ADHD or PCOS, we excluded all children with
mothers born outside of Sweden and repeated models 1 to 3
for the remaining 52,411 cases and 379,071 controls.
Because information on mothers’ medication use during
pregnancy was available for only a subsample of children born
in 2005 to 2008, we tabulated cases and controls exposed to
maternal PCOS and valproate, antipsychotic, spironolactone,
or metformin use during pregnancy without further analyses.
Finally, to assess whether more detailed information on
parental psychiatric history inﬂuenced the relationship
between maternal PCOS and offspring ADHD, model 2 was
repeated including the following speciﬁc diagnoses in the
mother and father: affective disorders (bipolar), nonaffective
psychosis, ADHD, and other psychiatric diagnoses.RESULTS
A higher proportion of mothers of ADHD cases had a
diagnosis of PCOS compared with mothers of noncases
(Table 1). ADHD cases were more likely to have younger
parents, a mother born in Sweden, parental history of psychi-
atric care, lower household income, lower parental education,
and obstetric complications and to be second born or later.
Maternal diagnosis of PCOS was associated with higher
odds of ADHD in both unadjusted (model 1 odds ratio [OR],
1.75; 95% conﬁdence interval [CI], 1.58–1.95) and adjusted
(model 2 OR, 1.42; 95% CI, 1.26–1.58) models (Table 2).
Further adjustment for obstetric complications did not sub-
stantially attenuate the OR for ADHD. Excluding cases of
ADHD with comorbid ASD attenuated the associations
between maternal PCOS and offspring ADHD (model 2 OR,
1.34; 95% CI, 1.18–1.52), and ORs were somewhat higher for
ADHD with comorbid ASD (model 2 OR, 1.76; 95% CI, 1.37–
2.26; Table 2). In sex-stratiﬁed analyses, ORs tended to be
higher among girls compared with boys (Table 3).
Among mothers with PCOS, 1.8% were underweight, 39.1%
were normal weight, 32.4% were overweight, and 26.7% were
obese in early pregnancy. Corresponding proportions among
mothers without PCOS were 3.7%, 67.7%, 20.9%, and 7.7%,
respectively. Maternal PCOS was associated with higher odds of
ADHD in the subset of women with BMI data; estimated ORs were
similar compared with the entire study sample (Supplemental
Table S1). The ORs were attenuated after adjustment for BMI
(model 4 OR, 1.25; 95% CI, 1.09–1.43; Supplemental Table S1). In
stratiﬁed analysis, we observed the highest odds of offspring
ADHD among obese women with PCOS and symptoms of
metabolic syndrome (Table 4). Trend analysis indicated that the
odds of ADHD increased with worsening cardiometabolic proﬁles
(Table 4).
In sensitivity analyses, excluding cases identiﬁed only by
record of prescription of ADHD medication did not substan-
tially change the OR (model 2 OR, 1.44; 95% CI, 1.27–1.63),
nor did adjusting for fertility treatment (model 2 OR, 1.44; 95%CI, 1.25–1.65), excluding children with mothers born outside of
Sweden (model 2 OR, 1.47; 95% CI, 1.3–1.67), or including
detailed information on parental psychiatric history (model 2
OR, 1.41; 95% CI, 1.25–1.58). Last, of the 9492 children (955
cases, 8537 controls) born in 2005 to 2008 in the study
population, no cases were exposed to maternal PCOS and
maternal use of valproate, antipsychotics, or spironolactone
during gestation. Three control individuals were exposed to
both maternal PCOS and metformin; no control individuals
were exposed to any of the other listed medications and
maternal PCOS.DISCUSSION
Maternal diagnosis of PCOS increased the risk for clinically
diagnosed ADHD in the offspring even after adjustment for
potential confounders. The increase in risk for ADHD remained
after excluding cases with comorbid ASD, indicating that maternal
PCOS increases the risk for ADHD independent of comorbidity
between ADHD and ASD. Our results show that the risk for ADHD
grew higher with worsening cardiometabolic proﬁles among
mothers with PCOS, such that children of mothers affected by
PCOS, obesity, and other features of metabolic syndrome had a
greater than twofold increased risk for ADHD.
To our knowledge, no previous study has examined the
relationship between maternal PCOS and offspring ADHD.
PCOS is the leading cause of anovulatory infertility, and prior
studies have found a relationship between fertility treatments,
particularly ovulation induction, and offspring ADHD (40,41).
Recent evidence suggests that the risk associated with fertility
treatments originates from the underlying causes of infertility
rather than the treatment itself (40).
Maternal PCOS increased the risk for ASD in a recent study
(22), and our results indicate that ADHD is associated with
maternal PCOS independent of comorbidity with ASD. Taken
together, these results suggest that maternal PCOS may have
broader detrimental effects on neurodevelopment. We
hypothesize that these effects may be mediated by excess
prenatal androgen exposure. Most women with PCOS have
clinical hypernadrogenemia that is aggravated by obesity
(42,43). During pregnancy, women with PCOS display
increased circulating androgen levels (21). Placentas of
women with PCOS show abnormal steroidogenesis and
increased capacity for producing androgens (20). Newborns
of women with PCOS have atypical levels of sex steroids,
including elevated androgen levels (44,45).
Prenatal exposure to sex hormones may inﬂuence neuro-
development and increase susceptibility for ADHD through a
range of mechanisms. During neurodevelopment, steroids
inﬂuence the formation of brain regions (9,10,46) and neuro-
logical processes, including the reward system, motor func-
tion, and spatial memory (46–48), that are impaired in ADHD.
Fetal testosterone levels are linked to abnormal brain lateral-
ization and reduced volume of the right hemisphere, as seen in
ADHD (49–51). Fetal steroids inﬂuence neuronal spine density
and synaptic plasticity that also appear aberrant in ADHD
(52,53). Aberrations in brain dopaminergic activity, a major
biological underpinning of ADHD, have been related to pre-
natal sex hormone exposure in animal models (54,55). Mater-
nal polymorphisms in the sex steroid pathway have beenBiological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 5
Table 2. ORs and 95% CIs of ADHD for Maternal PCOS in Birth Cohorts From 1984 to 2008 in the Swedish Population
Any ADHD ADHD With No ASD Comorbidity ADHD With ASD Comorbidity
No PCOS Maternal PCOS No PCOS Maternal PCOS No PCOS Maternal PCOS
Cases, n (%) 58,508 (99.3) 404 (0.7) 49,023 (99.4) 319 (0.6) 9485 (99.1) 85 (0.9)
Controls, n (%) 498,061 (99.6) 1937 (0.4) 417,085 (99.6) 1611 (0.4) 80,976 (99.6) 326 (0.4)
Model 1, OR (95% CI)a Ref 1.75 (1.58–1.95) Ref 1.66 (1.48–1.88) Ref 2.20 (1.73–2.80)
Model 2, OR (95% CI)b Ref 1.42 (1.26–1.58) Ref 1.34 (1.18–1.52) Ref 1.76 (1.37–2.26)
Model 3, OR (95% CI)c Ref 1.40 (1.25–1.56) Ref 1.32 (1.17–1.50) Ref 1.75 (1.36–2.24)
ADHD, attention-deﬁcit/hyperactivity disorder; ASD, autism spectrum disorder; CI, conﬁdence interval; OR, odds ratio; PCOS, polycystic ovary
syndrome; Ref, reference.
aModel 1: unadjusted.
bModel 2: adjusted for maternal age, paternal age, birth order, parental psychiatric history, household income, parental education, and mother’s
country of birth.
cModel 3: adjusted as above, with further adjustment for obstetric complications (Apgar score at 5 minutes, preterm birth, small for gestational
age, and preeclampsia).
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(56). Somewhat surprisingly, the risk associated with PCOS
appeared slightly elevated for girls compared with boys,
though risk estimates for boys and girls overlapped.
We observed that maternal PCOS was associated with a
somewhat higher risk for ADHD with comorbid ASD compared
to ADHD only. There has been increasing focus on the
comorbidity between ADHD and ASD in recent years. Overlap
between the disorders has been noted in terms of shared risk
factors, similarities in brain structure, and shared dimensions
of each disorder (11,57–59). Given the possibility that ADHD
with comorbid ASD represents a distinct subtype of ADHD,
current DSM-5 guidelines allow for clinicians to make an ASD
diagnosis in the context of ADHD (57,60). To date, more
research has been conducted regarding hormone exposures
in the prenatal environment for ASD compared to ADHD (12).
Our study adds further evidence of shared risk factors for
these disorders and highlights the utility of considering
comorbid diagnostic status because the relationship between
the prenatal environment and neurodevelopmental outcomes
may vary by subtypes of each disorder.
In addition to androgen excess, there are a host of
metabolic disturbances concomitant with PCOS, including
adiposity, insulin resistance, and hyperinsulinemia (13). Pre-
natal exposure to maternal overweight or obesity (32,61) and
hyperinsulinemia (62) have been associated with the risk for
offspring ADHD. Adjusting for BMI attenuated but did not fully
explain the relationship between PCOS and risk for ADHD in
our study, indicating that some of the risk could be attributedTable 3. ORs and 95% CIs of Maternal PCOS for ADHD Stratiﬁe
the Swedish Population
Male
No PCOS Matern
Cases, n (%) 40,191 (99.3) 282 (0
Controls, n (%) 341,444 (99.6) 1402 (0
Model 1, OR (95% CI)a Ref 1.69 (1
Model 2, OR (95% CI)b Ref 1.37 (1
ADHD, attention-deﬁcit/hyperactivity disorder; CI, conﬁdence interval; O
aModel 1: unadjusted.
bModel 2: adjusted for maternal age, paternal age, birth order, parental p
country of birth.
6 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalto elevated BMI in mothers with PCOS. Recent evidence
suggests that the association between maternal elevated BMI
and ADHD could be due to confounding by time-stable familial
factors (32). The hormonal and metabolic disturbances asso-
ciated with PCOS would be conserved over time within
mothers, and thus we were not able to use family-based
study designs to parse this question further. We observed a
trend of increasing risk for ADHD with worsening cardiometa-
bolic risk proﬁles of mothers with PCOS. Mothers with PCOS,
obesity, and other features of metabolic syndrome had the
highest risk. In women with PCOS, the androgen excess
collaborates with insulin resistance and hyperinsulinemia in
increasing adiposity and risk for metabolic syndrome, which in
turn exacerbate hormonal disturbances of PCOS in a positive-
feedback loop (43,63). As a result, obese women with PCOS
have more severe hyperandrogenemia and metabolic distur-
bances as compared with their normal-weight counterparts
(31,63). Apart from maternal hyperandrogenemia, maternal
obesity and hyperinsulinemia also inﬂuence the hormonal
and metabolic environment of the fetus by modulating pla-
cental aromatase activity and potentially by modulating fetal
steroidogenesis and gonadal programming (64–66). Maternal
obesity and metabolic syndrome also increase circulating
levels of inﬂammatory factors; maternal inﬂammation has been
proposed to play a role in the development of ADHD and ASD
(67–69). Further studies measuring biomarkers of the hormo-
nal, inﬂammatory, and metabolic environment of the mother
and fetus are necessary to understand the mechanisms linking
maternal PCOS to ADHD and its subtypes in the offspring.d by Sex of the Child in Birth Cohorts From 1984 to 2008 in
Female
al PCOS No PCOS Maternal PCOS
.7) 18,317 (99.3) 122 (0.7)
.4) 156,617 (99.7) 535 (0.3)
.49–1.92) Ref 1.92 (1.58–2.35)
.20–1.57) Ref 1.53 (1.24–1.88)
R, odds ratio; PCOS, polycystic ovary syndrome; Ref, reference.
sychiatric history, household income, parental education, and mother’s
Table 4. ORs and 95% CIs by Maternal PCOS Symptom Severity for ADHD in Birth Cohorts From 1984 to 2008 in the
Swedish Population
No PCOS Maternal PCOS
Maternal PCOS
1 Overweight
Maternal PCOS
1 Obesity
Maternal PCOS 1 Obesity
1 Metabolic Syndromea p Trend
Cases, n (%) 41,084 (99.3) 106 (0.3) 101 (0.2) 88 (0.2) 7 (,0.1)
Controls, n (%) 283,185 (99.6) 521 (0.2) 396 (0.1) 297 (0.1) 17 (,0.1)
Model 1, OR
(95% CI)b
Ref 1.42 (1.15–1.75) 1.82 (1.46–2.27) 2.09 (1.65–2.66) 2.97 (1.23–7.18) ,.001
Model 2, OR
(95% CI)c
Ref 1.11 (0.89–1.39) 1.56 (1.24–1.96) 1.68 (1.31–2.17) 2.59 (1.02–6.58) ,.001
ADHD, attention-deﬁcit/hyperactivity disorder; CI, conﬁdence interval; OR, odds ratio; PCOS, polycystic ovary syndrome; Ref, reference.
aMetabolic syndrome deﬁned as obesity and a diagnosis of essential hypertonia and/or diabetes.
bModel 1: unadjusted.
cModel 2: adjusted for maternal age, paternal age, birth order, parental psychiatric history, household income, parental education, and mother’s
country of birth.
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explain some of the associations observed in this study. A small
clinical study compared ADHD rating scale scores among women
with PCOS and healthy controls and found the former to have
more ADHD symptoms (70), indicating that there may be some
shared genetic risk between the two disorders. We observed little
evidence that the association is explained by increased risk for
obstetric complications among mothers with PCOS.
Strengths of our study are the large population-based
sample within a publicly funded universal access health care
setting, prospectively collected outcome data, and information
on many potential confounders. Our study has a number of
limitations. The observed prevalence of PCOS was lower than
previous estimates, suggesting that PCOS may be unrecog-
nized in many Swedish women. Although register-based
diagnoses are objective and not subject to recall bias, we
might have captured women with more severe PCOS as
exposed and thus our ﬁndings may not be generalizable to
all women with PCOS. Likewise, case ascertainment was
based on registered diagnoses and drug treatment for ADHD
and may reﬂect more severe cases. Data on mothers’ med-
ication during pregnancy were available for only a small
subsample of the study population. Thus, it was not possible
to examine whether pharmacological interventions for mothers
with PCOS, such as metformin use, could attenuate risk.
Further, it is not possible to rule out that valproate or
antipsychotic use during pregnancy might confound the
relationship between maternal PCOS and offspring ADHD. In
this study, there was little evidence of use of these medica-
tions during pregnancy among mothers with PCOS for the
subsample of children born in 2005 to 2008. The question of
whether maternal medication use modulates the risks for
neurodevelopmental disorders in the offspring associated with
maternal PCOS remains an important goal for future research
in this area. Data on BMI were available for only a subsample
of the study population. However, there are few differences
between women with and without baseline BMI data in
characteristics such as socioeconomic factors, suggesting
that BMI data are missing at random (33).
Conclusions
Maternal PCOS may subtly inﬂuence the neurodevelopment of the
offspring, resulting in increased risk for neurodevelopmentaldisorders such as ADHD. The apparent risk increased with
worsening maternal cardiometabolic proﬁles. Encouraging women
with PCOS to begin pregnancy at a healthy weight and to adhere
closely to gestational weight gain guidelines could potentially
decrease the risk for ADHD for their offspring. Given the impact
that ADHD has globally, there is a need for delineation of the
mechanisms underlying the relationship with maternal PCOS,
particularly the role of prenatal androgens and metabolic distur-
bances in the etiology of neurodevelopmental disorders.
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